Novo Nordisk registers four Phase 3 AMBITION trials for zenagamtide in type 2 diabetesNov 12Weekly roundup, 5 itemsNovo Nordisk A/SsemaglutideUpdated
Novo Nordisk registers two zenagamtide switch studies; IMPLEMENT HF recruitment continuesOct 16Weekly roundup, 3 itemsNovo Nordisk A/SsemaglutideUpdated
Novo Nordisk registers Phase 3 cardiovascular outcomes trial for zenagamtide, acronym AMBIENCEOct 9Weekly roundup, 2 itemsNovo Nordisk A/Stirzepatide
Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world dataOct 2Weekly roundup, 9 itemsCagrisemaNNC0705-0002Updated
Novo Nordisk registers two Phase 1 PK trials for zenagamtide and NNC0537-1482Sep 11Weekly roundup, 2 itemsNNC0537-1482Novo Nordisk A/S
Novo Nordisk registers Phase 3 zenagamtide trial in T2D and first-in-human study for NNC0705-0002Sep 1Weekly roundup, 2 itemsNNC0705-0002Novo Nordisk A/S
Novo Nordisk registers Phase 3 obesity trial for zenagamtide; MTC safety study enrollingJul 22Weekly roundup, 2 itemsNovo Nordisk A/Szenagamtide